BioCentury | Jul 17, 2019
Company News

On heels of trial readout, Frequency out-licenses hearing loss therapy to Astellas

...deal. The therapy’s active substance is heparin-binding EGF-like growth factor (HBEGF; DTR). Allison Johnson, Senior Writer FX-322 Astellas Pharma Inc. Frequency Therapeutics Inc. Heparin-binding EGF-like growth factor (HBEGF) (DTR) AU-935 Auration...
BioCentury | Sep 1, 2016
Distillery Therapeutics

Therapeutics: Lipoteichoic acid (LTA); heparin-binding EGF-like growth factor (HBEGF; DTR)

...a compound composed of glycans from C. difficile LTA conjugated to the immunogenicity-enhancing carrier protein HBEGF...
...C. difficile, in Phase II testing for CDI. TARGET/MARKER/PATHWAY: Lipoteichoic acid (LTA) ; heparin-binding EGF-like growth factor (HBEGF; DTR...
BioCentury | Mar 18, 2013
Strategy

Japan's biggest biotech

...I/II in U.S. Regimmune Corp. has worldwide rights KHK2866 (A) Humanized antibody against heparin-binding EGF-like growth factor (HBEGF; DTR...
BioCentury | Jul 29, 2010
Targets & Mechanisms

Attacking cancer's secretive side

...ligands that were expressed by a human pancreatic cancer cell line: TGFA and heparin-binding EGF-like growth factor ( HBEGF...
...cervical and biliary cancers. Yarden said the team's planned work includes humanizing the anti-TGFA and anti-HBEGF...
BioCentury | Jul 15, 2010
Distillery Therapeutics

Indication: Cancer

...Licensing status Publication and contact information Cancer Pancreatic cancer Transforming growth factor-a (TGFA; TGFa); heparin-binding EGF-like growth factor (HBEGF...
...xenograft model of pancreatic cancer, gemcitabine plus two antibodies against the EGFR ligands TGFa and HBEGF...
BioCentury | Jun 14, 1999
Clinical News

BioSpecifics, Tufts University regulatory update

...U.S. Patent No. 5,851,522 covering an enzyme formulation consisting of the collagenase enzyme and the hbEGF...
Items per page:
1 - 6 of 6